All
Neuropathy and Chemo Brain: The Lasting Effects of One Nurse-Turned-Patient's Road to Recovery
June 28th 2017Anne Llewellyn knows how to be a good nurse. For nearly 40 years, she took care of others in the Emergency Department and Respiratory Intensive Care. Her perspective of the health care industry changed a bit after she became the patient. Diagnosed with a central nervous system brain tumor in November 2014, Llewellyn had to become her own advocate, along with the help of her husband.
Combination Is Active in Checkpoint Inhibitor-Refractory Patients With Melanoma
June 27th 2017Promising clinical activity and acceptable safety was shown when the PD-1 inhibitor Keytruda (pembrolizumab) was given with the HDAC inhibitor entinostat for patients with melanoma who were refractory to immune checkpoint inhibitors.
Expert Weighs In: Active Surveillance in Prostate Cancer
June 26th 2017When it comes to active surveillance and prostate-specific antigen (PSA) screening for localized prostate cancer, the paradigm has been shifting and the debate over which is correct has been raging on in recent years, says Andrew Stephenson, M.D.
Combination Approved for BRAF-Positive Lung Cancer
June 23rd 2017The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) gained approval from the Food and Drug Administration (FDA) for the treatment of patients with BRAF V600–positive advanced or metastatic non–small cell lung cancer (NSCLC).
FDA Approves Rituxan Hycela for Blood Cancers
June 22nd 2017Rituxan Hycela (rituximab) was granted approval by the Food and Drug Administration (FDA) for adult patients with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL) and previously untreated and previously treated chronic lymphocytic leukemia (CLL).